Payment overview · 2025
General Payments
$596.47
36 reported records · 9 companies
Healthcare provider profile · identity verified
Jose Luis Milera, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · LAREDO, TX · NPI 1144689639
Verified facts
What the public records show
CMS Open Payments records show Jose Luis Milera, FNP received $596.47 in general payments during 2025 across 36 reported records.
Novo Nordisk Inc accounted for 32.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 245 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $194.07 | 32.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.08 | 23.8% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $71.66 | 12.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $52.72 | 8.8% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $47.30 | 7.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.29 | 4.9% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.45 | 3.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.07 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.83 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $596.47 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.11 | 13 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $121.08 | 12 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.94 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.13 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $71.66 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.98 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $52.72 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $47.30 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.29 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $22.45 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.83 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $17.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 80 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 27 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 314 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 87 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 245 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
314 | 95 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
314 | 95 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
87 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
55 | 22 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
245 | 87 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
59 | 25 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
27 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 873 | 352 |
| Metformin Hcl | Metformin Hcl | 393 | 152 |
| Farxiga | Dapagliflozin Propanediol | 385 | 126 |
| Losartan Potassium | Losartan Potassium | 335 | 143 |
| Jardiance | Empagliflozin | 314 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 309 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 125 |
| Lisinopril | Lisinopril | 266 | 115 |
| Levothyroxine Sodium | Levothyroxine Sodium | 256 | 107 |
| Metoprolol Succinate | Metoprolol Succinate | 255 | 105 |
| Ozempic | Semaglutide | 245 | 87 |
| Pioglitazone Hcl | Pioglitazone Hcl | 230 | 121 |
| Azithromycin | Azithromycin | 206 | 186 |
| Tamsulosin Hcl | Tamsulosin Hcl | 205 | 102 |
| Omeprazole | Omeprazole | 157 | 92 |
| Dexamethasone | Dexamethasone | 133 | 127 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 48 |
| Furosemide | Furosemide | 123 | 58 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 121 | 55 |
| Metformin Hcl Er | Metformin Hcl | 112 | 54 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 105 | 93 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 47 |
| Meloxicam | Meloxicam | 99 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 95 | 66 |
| Linzess | Linaclotide | 92 | 51 |
| Mounjaro | Tirzepatide | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 52 |
| Tizanidine Hcl | Tizanidine Hcl | 86 | 55 |
| Carvedilol | Carvedilol | 83 | 29 |
| Gabapentin | Gabapentin | 83 | 32 |
| Alendronate Sodium | Alendronate Sodium | 81 | 37 |
| Entresto | Sacubitril/Valsartan | 80 | 34 |
| Levofloxacin | Levofloxacin | 80 | 64 |
| Trazodone Hcl | Trazodone Hcl | 80 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 36 |
| Donepezil Hcl | Donepezil Hcl | 74 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 61 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 45 |
| Finasteride | Finasteride | 64 | 35 |
| Telmisartan | Telmisartan | 62 | 29 |
| Eliquis | Apixaban | 61 | 21 |
| Meclizine Hcl | Meclizine Hcl | 60 | 45 |
| Montelukast Sodium | Montelukast Sodium | 60 | 34 |
| Rybelsus | Semaglutide | 59 | 25 |
| Cefdinir | Cefdinir | 57 | 52 |
| Allopurinol | Allopurinol | 56 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 56 | 23 |
| Baclofen | Baclofen | 55 | 38 |
| Trulicity | Dulaglutide | 55 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 54 | 17 |
| Xarelto | Rivaroxaban | 54 | 24 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 22 |
| Cephalexin | Cephalexin | 51 | 48 |
| Spironolactone | Spironolactone | 51 | 26 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 41 |
| Tresiba Flextouch U-200 | Insulin Degludec | 49 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 48 | 29 |
| Tramadol Hcl | Tramadol Hcl | 48 | 23 |
| Famotidine | Famotidine | 46 | 34 |
| Paxlovid | Nirmatrelvir/Ritonavir | 46 | 45 |
| Myrbetriq | Mirabegron | 44 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 34 |
| Memantine Hcl | Memantine Hcl | 41 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 22 |
| Naproxen | Naproxen | 40 | 34 |
| Sertraline Hcl | Sertraline Hcl | 39 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 39 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 18 |
| Nifedipine Er | Nifedipine | 36 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 36 | 35 |
| Simvastatin | Simvastatin | 36 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 21 |
| Clonidine Hcl | Clonidine Hcl | 34 | 20 |
| Dapagliflozin | Dapagliflozin Propanediol | 34 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 33 | 12 |
| Prednisone | Prednisone | 32 | 27 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 16 |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 30 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 29 | 19 |
| Fluconazole | Fluconazole | 29 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 29 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 28 | 27 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | 14 |
| Gemtesa | Vibegron | 27 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 27 | 11 |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 25 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 24 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Lactulose | Lactulose | 23 | 20 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Enalapril Maleate | Enalapril Maleate | 22 | 11 |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | 19 |
| Valsartan | Valsartan | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 22 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | 15 |
| Ibuprofen | Ibuprofen | 20 | 15 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 19 | 16 |
| Celecoxib | Celecoxib | 18 | suppressed |
| Constulose | Lactulose | 18 | 14 |
| Megestrol Acetate | Megestrol Acetate | 18 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | 12 |
| Tradjenta | Linagliptin | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 17 |
| Atenolol | Atenolol | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | 13 |
| Terbinafine Hcl | Terbinafine Hcl | 17 | 15 |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 14 |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 14 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 14 | 14 |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Prenatal Vitamin Plus Low Iron | Pnv,calcium 72/Iron/Folic Acid | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 11 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $596.47 · 36 records | Novo Nordisk Inc | ENTRESTO, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error